Assessing bleeding risk in patients taking anticoagulants.

PubWeight™: 0.88‹?›

🔗 View Article (PMC 3888359)

Published in J Thromb Thrombolysis on April 01, 2013

Authors

Marwa Shoeb1, Margaret C Fang

Author Affiliations

1: Division of Hospital Medicine, University of California, San Francisco, CA 94143, USA.

Articles cited by this

Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97

Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 10.75

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29

Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med (2009) 9.17

Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet (2009) 6.83

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41

A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol (2011) 5.06

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66

Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med (1989) 3.65

Development of a contemporary bleeding risk model for elderly warfarin recipients. Chest (2006) 3.54

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atrial fibrillation) study. J Am Coll Cardiol (2012) 3.49

Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med (1998) 3.44

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29

Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med (2003) 3.18

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med (2004) 3.06

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J (2006) 3.05

Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med (2012) 3.04

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost (2008) 2.60

Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 2.54

Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med (2007) 2.20

Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16

Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med (1999) 2.07

The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost (2006) 2.04

Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00

Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke (2005) 1.85

Scores to predict major bleeding risk during oral anticoagulation therapy: a prospective validation study. Am J Med (2012) 1.81

Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med (2005) 1.61

Prospective, multicenter validation of prediction scores for major bleeding in elderly patients with venous thromboembolism. J Thromb Haemost (2013) 1.45

Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke (2004) 1.23

Bleeding risk in 'real world' patients with atrial fibrillation: comparison of two established bleeding prediction schemes in a nationwide cohort. J Thromb Haemost (2011) 1.23

Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a "real-world" population with atrial fibrillation receiving anticoagulant therapy. Chest (2013) 1.22

Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke (2012) 1.10

Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med (2007) 1.08

A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost (2000) 1.03

Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol (2012) 0.97

Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am J Med (2012) 0.92

Articles by these authors

Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 7.48

A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09

Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 5.27

The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med (2009) 4.71

Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 4.01

Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation (2009) 2.18

Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes (2009) 1.29

Current issues in patient adherence and persistence: focus on anticoagulants for the treatment and prevention of thromboembolism. Patient Prefer Adherence (2010) 1.26

Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med (2009) 1.17

A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. J Am Heart Assoc (2013) 1.14

Rates and predictors of plans for inferior vena cava filter retrieval in hospitalized patients. J Gen Intern Med (2010) 1.00

Performance of an online translation tool when applied to patient educational material. J Hosp Med (2011) 0.84

Venous thromboembolism prophylaxis in the United States: still room for improvement. J Gen Intern Med (2010) 0.83

Preparing for "diastole": advanced training opportunities for academic hospitalists. J Hosp Med (2006) 0.81

CHA2DS2-VASc risk scheme: not ready for clinical use. Chest (2010) 0.76

Hazards of hospitalization: more than just "never events". Arch Intern Med (2011) 0.75

The international normalized ratio range of 2.0 to 3.0 remains appropriate for atrial fibrillation. Arch Intern Med (2009) 0.75

Contemporary use of dual antiplatelet therapy for preventing cardiovascular events. Am J Manag Care (2014) 0.75

Care as a continuum: will hospital outcomes be influenced by outpatient care? J Hosp Med (2014) 0.75

Selecting the optimal stroke prevention therapy in atrial fibrillation. Ann Intern Med (2011) 0.75

Anticoagulation in people with atrial fibrillation. BMJ (2011) 0.75

Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis (2005) 0.75

Atrial fibrillation: stroke prevention in older adults. Clin Geriatr Med (2012) 0.75